StemCells Inc  

(Public, NASDAQ:STEM)   Watch this stock  
Find more results for STEM
0.00 (-0.29%)
After Hours: 1.71 -0.03 (-1.44%)
Jul 22, 6:41PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.72 - 1.76
52 week 1.15 - 2.43
Open 1.75
Vol / Avg. 0.00/4.94M
Mkt cap 118.18M
P/E     -
Div/yield     -
EPS -0.59
Shares 68.11M
Beta 1.51
Inst. own 9%
Jul 28, 2014
Q2 2014 StemCells, Inc. Earnings Release (Estimated) Add to calendar
Jun 25, 2014
StemCells Inc at Biotechnology Industry Organization (BIO) International Convention
Jun 19, 2014
StemCells Inc Conference Call to discuss the interim results from the Phase I/II clinical trial of HuCNS-SC cells in dry AMD
Jun 11, 2014
StemCells, Inc. Annual Shareholder Meeting
Jun 4, 2014
StemCells, Inc. at LD Micro Invitational - Webcast
May 14, 2014
Q1 2014 StemCells, Inc. Earnings Conference Call - Webcast
May 14, 2014
Q1 2014 StemCells, Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -2244.69% -2197.28%
Operating margin -2032.43% -2377.31%
EBITD margin - -2284.18%
Return on average assets -77.98% -73.72%
Return on average equity -270.35% -182.73%
Employees 58 -
CDP Score - -


United States - Map
+1-650-4753100 (Phone)
+1-510-4564001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


StemCells, Inc. (StemCells) is engaged in the research, development, and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The Company is focused on developing and commercializing stem and progenitor cells as the basis for therapeutics and therapies, and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. The Company�s primary research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The Company has two therapeutic product development programs, including its CNS Program, which is developing applications for HuCNS-SC cells, its human neural stem cell product candidate, and its Liver Program, which is characterizing the Company�s human liver cells as a therapeutic product.

Officers and directors

John J. Schwartz Ph.D. Independent Chairman of the Board
Age: 79
Bio & Compensation  - Reuters
Martin M. McGlynn President, Chief Executive Officer, Director
Age: 67
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Gregory T. Schiffman Chief Financial Officer, Executive Vice President - Finance
Bio & Compensation  - Reuters
Ann Tsukamoto Ph.D. Executive Vice President - Scientific and Strategic Alliances
Age: 61
Bio & Compensation  - Reuters
Kenneth Stratton J.D. General Counsel
Age: 45
Bio & Compensation  - Reuters
Alan O. Trounson Ph.D. Director
Bio & Compensation  - Reuters
Irving L. Weissman M.D. Director
Age: 73
Bio & Compensation  - Reuters
Eric H. Bjerkholt Independent Director
Age: 54
Bio & Compensation  - Reuters
R. Scott Greer Independent Director
Age: 55
Bio & Compensation  - Reuters
Ricardo B. Levy Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters